Melanoma is the 7th most common cancer in women and 6th most common cancer in men in the United States. The incidence of melanoma in California, a state with high sun-exposure, is the second most common of all cancers in young people under the age of 40. The 5-year overall survival for young people with malignant melanoma, presenting as a localized region, exceeds 90%. However, despite the lesser disease status, localized melanoma accounts for approximately 10% of all melanoma deaths in young people. Even worse, the 5-year overall survival for regional disease and distant metastatic disease is 65% and 15% respectively. Despite the fact that adolescents and young adults can tolerate high doses of treatment therapies they continue to be treated under less aggressive treatment adult-based guidelines. As we look forward it is important to continue to understand and learn more about the biology of melanomas in these different age groups especially through the role of immunotherapies as well as genetic lesions and progression markers of melanoma.
Source: Kirkwood J, Jukic D, Averbook B et al. Melanoma in Pediatric, Adolescent, and Young Adult Patients. Semin Oncol. 2009; 36:419-431.
Pediatric Melanoma and Atypical Melanocytic Neoplasms.
Cancer Treat Res. 2016;167:331-69
Authors: Sreeraman Kumar R, Messina JL, Reed D, Navid F, Sondak VK
Melanoma is uncommon in the pediatric age range, but is increasing in frequency and often presents with...
Increased risk of second malignant neoplasms in adolescents and young adults with cancer.
Cancer. 2015 Oct 6;
Authors: Lee JS, DuBois SG, Coccia PF, Bleyer A, Olin RL, Goldsby RE
BACKGROUND: The authors describe the...
Adolescent and young adult patients with cancer: a milieu of unique features.
Nat Rev Clin Oncol. 2015 May 26;
Authors: Sender L, Zabokrtsky KB
Adolescent and young adult (AYA) patients with cancer are a unique category of patients who, depending on age at time...
A case of anti-MDA5-positive rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis ameliorated by rituximab, in addition to standard immunosuppressive treatment.
Mod Rheumatol. 2015 Mar 12;:1-5
Authors: Koichi Y, Aya Y, Megumi U...
Comparison of survival at adult versus pediatric treatment centers for rare pediatric tumors in an adolescent and young adult (AYA) population in the State of Georgia.
Pediatr Blood Cancer. 2015 Mar;62(3):456-62
Authors: Cash T, Qayed M, Ward KC, Mertens AC, Rapkin L
Insurance status and distant-stage disease at diagnosis among adolescent and young adult patients with cancer aged 15 to 39 years: National Cancer Data Base, 2004 through 2010.
Cancer. 2014 Jan 28;
Authors: Robbins AS, Lerro CC, Barr RD
BACKGROUND: The percentage of...
Trends in incidence of primary cutaneous malignancies in children, adolescents, and young adults: A population-based study.
Pediatr Blood Cancer. 2013 Oct 30;
Authors: Senerchia AA, Ribeiro KB, Galindo CR
BACKGROUND: Skin cancer incidence among young adults is rising;...
Cancer in adolescents and young adults in countries with limited resources.
Curr Oncol Rep. 2013 Aug;15(4):332-46
Authors: Magrath I, Epelman S
Cancer in adolescents and young adults (AYA) represents a higher fraction of all cancer in countries that are still...
The Adolescent and Young Adult With Cancer: State of the Art-Epithelial Cancer.
Curr Oncol Rep. 2013 Jun 11;
Authors: Ferreira CG, de Melo AC, Nogueira-Rodrigues A
The adolescent and young adult (AYA) is defined as a patient of 15 to 39 years of age at initial...
Cancer Incidence and Survival in Adolescents and Young Adults in France, 2000-2008.
Pediatr Hematol Oncol. 2013 Jan 30;
Authors: Desandes E, Lacour B, Belot A, Molinie F, Delafosse P, Tretarre B, Velten M, Sauleau EA, Woronoff AS, Guizard AV, Ganry O, Bara S, Grosclaude P,...
Cancer in adolescents and young adults (15-29 years): A population-based study in the Netherlands 1989-2009.
Acta Oncol. 2012 Aug 30;
Authors: Aben KK, van Gaal C, van Gils NA, van der Graaf WT, Zielhuis GA
Background. Cancer among adolescents and young adults (AYAs; 15-29 years old) is relatively rare but its incidence is increasing worldwide. To define the extent and nature of the AYA patients, this population-based study was performed to explore trends in cancer incidence...
Immunotherapy for malignant melanoma--tracing Ariadne's thread through the labyrinth.
Eur J Cancer. 2009 Sep;45(13):2266-73
Authors: Grange JM, Krone B, Stanford JL
A working group (FEBIM) within the European Organisation for Research and...
from patients, caregivers and medical professionals dealing with this disease and many other diseases